Status:
COMPLETED
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Hemorrhagic Hereditary Telangiectasia
HHT
Eligibility:
All Genders
18+ years
Brief Summary
Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT. We studied the efficacy of bevacizumab on severe bleeding in HHT patien...
Eligibility Criteria
Inclusion
- Patient included in BABH study
Exclusion
- Patients opposition
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2022
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT06039124
Start Date
September 1 2021
End Date
August 1 2022
Last Update
September 15 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Médecine Interne et Maladies Vasculaires + Service Neuropédiatrie et neurochirurgie de l'enfant - CHU Angers
Angers, France, 49933
2
Hôpital Ambroise Paré
Boulogne-Billancourt, France
3
CHU de Montpellier-Hôpital St Eloi
Montpellier, France